Document is current
Any future updates will be listed below
-
Authors
Khattri, Arun https://orcid.org/0000-0002-9264-9549
Sheikh, Nizamuddin
Agrawal, Nikhil
Kaushik, Sandeep
Kochanny, Sara
Ginat, Daniel
Lingen, Mark W.
Blair, Elizabeth
Seiwert, Tanguy Y.
- License Information
-
More Information
Article History
Received: 22 March 2024
Revised: 4 July 2024
Accepted: 15 July 2024
First Online: 31 July 2024
Competing interests
: Arun Khattri received the financial support from the Department of Biotechnology, Government of India, in the form of Ramalingaswami Fellowship. The funding agency played no role in the study design, analysis, and interpretation of the results. Tanguy Y. Seiwert reports institutional research funding from Regeneron, Merck/MSD, BMS, Genentech, Cue Biopharma, Nanobiotix, Seattle Genetics, Exelixis, Astra Zeneca, IOBiotech, and Kura Oncology; and advisory board and consulting fees from Regeneron, Merck/MSD, Arcus, Astra Zeneca, Regeneron, IOBiotech, Seattle Genetics, Surface Oncology, Sanofi, iTeos, Innate Pharma, EMD Serono, Exelixis, Vir Therapeutics, and Eisei. He is on the DSMB for BioNTech, and the steering committee for IOBiotech.
